Why the study?
Does the totally subcutaneous implantable-defibrillator (S-ICD) provide safe and effective therapy in patients requiring an ICD?
Population
472 patients with S-ICD implants, mean age 49 ± 18 years, 72% male, mean LVEF 42%, international cohort.
Design
Cohort
Follow-up
mean 558 days (median 498 days)
Authors
Loading...
Supports S-ICD safety and efficacy in real-world registry; extends observational data but leaves open need for randomized confirmation.
Does the totally subcutaneous implantable-defibrillator (S-ICD) provide safe and effective therapy in patients requiring an ICD?
The S-ICD demonstrates appropriate system performance, efficacy, and safety comparable to conventional ICDs in a real-world international registry.
Lambiase et al. (2014) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: